» Articles » PMID: 12967473

Genetic Mapping of Allelic Loss on Chromosome 6q Within Heterogeneous Prostate Carcinoma

Overview
Journal Cancer Sci
Specialty Oncology
Date 2003 Sep 12
PMID 12967473
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

A number of genetic events have been reported in prostate carcinogenesis, including frequent loss of heterozygosity (LOH) on chromosomes 8q, 10q, 16q and 18q. In samples of heterogeneous, multifocal prostate carcinomas, we focused on chromosome 6q using PCR-based techniques with 15 microsatellite markers to identify the specific 6q deletion within tumors. LOH of one or more polymorphic markers was detected in 10 of 21 tumors (48%). Two of these 10 tumors demonstrated LOH in all cancerous foci at specific loci and 4 tumors showed deletion in one focus. Different deletion patterns were found in 3 tumors when different polymorphic markers were used. In 90% of tumors showing LOH in one or more foci, however, two common regions of LOH were identified; one at 1.81 cM on 6q15-16.3 between markers D6S1631 and D6S1056, and the other at 5.11 cM on 6q16-21 between markers D6S424 and D6S283. By RT-PCR analysis, the TAK1 gene located at these loci did not correlate with LOH status, indicating that TAK1 is not a target gene in prostate carcinoma. The 6q deletion occurs heterogeneously and LOH was more frequent in tumors of higher pathological stages, implying that this alteration is a late event in prostate carcinogenesis. Because prostate carcinomas are genetically multicentric and of multifocal origin, it remains unclear whether the foci containing 6q deletions specifically expand within tumors or to what extent they contribute to the histological heterogeneity characteristic of the disease.

Citing Articles

Alternative Promoters of () Gene in Human Carcinoma Cell Lines Are Regulated by Differential Methylation of CpG Dinucleotides.

Zhawar V, Kandpal R, Athwal R Genes (Basel). 2022; 13(3).

PMID: 35328043 PMC: 8954616. DOI: 10.3390/genes13030490.


Assessing the Diagnostic Value of Plasma-Free DNA in Prostate Cancer Screening.

Seyedolmohadessin S, Akbari M, Nourmohammadi Z, Basiri A, Pourmand G Iran Biomed J. 2018; 22(5):331-7.

PMID: 29475366 PMC: 6058185. DOI: 10.29252/ibj.22.5.331.


A spatiotemporal hypothesis for the regulation, role, and targeting of AMPK in prostate cancer.

Khan A, Frigo D Nat Rev Urol. 2017; 14(3):164-180.

PMID: 28169991 PMC: 5672799. DOI: 10.1038/nrurol.2016.272.


Cisplatin causes cell death via TAB1 regulation of p53/MDM2/MDMX circuitry.

Zhu Y, Regunath K, Jacq X, Prives C Genes Dev. 2013; 27(16):1739-51.

PMID: 23934659 PMC: 3759692. DOI: 10.1101/gad.212258.112.


The identification of chromosomal translocation, t(4;6)(q22;q15), in prostate cancer.

Shan L, Ambroisine L, Clark J, Yanez-Munoz R, Fisher G, Kudahetti S Prostate Cancer Prostatic Dis. 2010; 13(2):117-25.

PMID: 20177423 PMC: 2917588. DOI: 10.1038/pcan.2010.2.


References
1.
Berggren M, Husbeck B, Samulitis B, Baker A, Gallegos A, Powis G . Thioredoxin peroxidase-1 (peroxiredoxin-1) is increased in thioredoxin-1 transfected cells and results in enhanced protection against apoptosis caused by hydrogen peroxide but not by other agents including dexamethasone, etoposide, and doxorubicin. Arch Biochem Biophys. 2001; 392(1):103-9. DOI: 10.1006/abbi.2001.2435. View

2.
Mazurenko N, Attaleb M, Gritsko T, Semjonova L, Pavlova L, Sakharova O . High resolution mapping of chromosome 6 deletions in cervical cancer. Oncol Rep. 1999; 6(4):859-63. DOI: 10.3892/or.6.4.859. View

3.
Bostwick D, Pacelli A, Lopez-Beltran A . Molecular biology of prostatic intraepithelial neoplasia. Prostate. 1996; 29(2):117-34. DOI: 10.1002/(SICI)1097-0045(199608)29:2<117::AID-PROS7>3.0.CO;2-C. View

4.
Jamain S, Betancur C, Quach H, Philippe A, Fellous M, Giros B . Linkage and association of the glutamate receptor 6 gene with autism. Mol Psychiatry. 2002; 7(3):302-10. PMC: 2547854. DOI: 10.1038/sj.mp.4000979. View

5.
Nupponen N, Kakkola L, Koivisto P, Visakorpi T . Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol. 1998; 153(1):141-8. PMC: 1852946. DOI: 10.1016/S0002-9440(10)65554-X. View